ACAD
36.045
-2.315
-6.035%
AEMD
0.196
-0.01
-4.6341%
APRI
1.62
+0.01
+0.62%
ARNA
4.22
-0.27
-6.01%
ATEC
1.41
0.00
0.00%
CNAT
6.35
-0.31
-4.65%
CRXM
0.415
+0.061
+17.397%
CYTX
0.915
-0.07
-7.107%
DXCM
67.56
-1.87
-2.69%
GNMK
10.35
-0.34
-3.18%
HALO
15.78
-1.08
-6.41%
ILMN
183.71
-5.88
-3.10%
INNV
0.145
0.00
0.00%
INO
10.055
-0.295
-2.850%
ISCO
0.074
-0.001
-0.6757%
ISIS
62.02
-4.35
-6.55%
LGND
87.3
-2.45
-2.73%
LPTN
2.23
0.00
0.00%
MBVX
3.17
-0.19
-5.65%
MEIP
2.07
-0.09
-4.17%
MNOV
3.76
-0.33
-8.07%
MRTX
26.98
-0.89
-3.19%
MSTX
0.476
-0.014
-2.857%
NBIX
39.5
-3.87
-8.92%
NUVA
43.36
-0.63
-1.43%
ONCS
0.291
+0.023
+8.582%
ONVO
4.87
-0.32
-6.17%
OREX
6.95
-0.41
-5.57%
OTIC
28.58
-3.22
-10.13%
QDEL
23.41
+0.03
+0.13%
RCPT
156.22
-13.66
-8.04%
RGLS
14.59
-2.9
-16.58%
RMD
64.55
-1.15
-1.75%
SCIE
0.019
-0.007
-27.95367%
SPHS
0.75
-0.05
-6.24%
SRNE
9.36
-1.16
-11.03%
TROV
8.27
-0.53
-6.02%
VICL
0.96
-0.05
-4.48%
VOLC
17.99
0.00
0.00%
ZGNX
1.41
-0.13
-8.44%
ACAD
36.045
-2.315
-6.035%
AEMD
0.196
-0.01
-4.6341%
APRI
1.62
+0.01
+0.62%
ARNA
4.22
-0.27
-6.01%
ATEC
1.41
0.00
0.00%
CNAT
6.35
-0.31
-4.65%
CRXM
0.415
+0.061
+17.397%
CYTX
0.915
-0.07
-7.107%
DXCM
67.56
-1.87
-2.69%
GNMK
10.35
-0.34
-3.18%
HALO
15.78
-1.08
-6.41%
ILMN
183.71
-5.88
-3.10%
INNV
0.145
0.00
0.00%
INO
10.055
-0.295
-2.850%
ISCO
0.074
-0.001
-0.6757%
ISIS
62.02
-4.35
-6.55%
LGND
87.3
-2.45
-2.73%
LPTN
2.23
0.00
0.00%
MBVX
3.17
-0.19
-5.65%
MEIP
2.07
-0.09
-4.17%
MNOV
3.76
-0.33
-8.07%
MRTX
26.98
-0.89
-3.19%
MSTX
0.476
-0.014
-2.857%
NBIX
39.5
-3.87
-8.92%
NUVA
43.36
-0.63
-1.43%
ONCS
0.291
+0.023
+8.582%
ONVO
4.87
-0.32
-6.17%
OREX
6.95
-0.41
-5.57%
OTIC
28.58
-3.22
-10.13%
QDEL
23.41
+0.03
+0.13%
RCPT
156.22
-13.66
-8.04%
RGLS
14.59
-2.9
-16.58%
RMD
64.55
-1.15
-1.75%
SCIE
0.019
-0.007
-27.95367%
SPHS
0.75
-0.05
-6.24%
SRNE
9.36
-1.16
-11.03%
TROV
8.27
-0.53
-6.02%
VICL
0.96
-0.05
-4.48%
VOLC
17.99
0.00
0.00%
ZGNX
1.41
-0.13
-8.44%
Home » Bio: Keith Murphy

Bio: Keith Murphy

Keith Murphy, chairman and chief executive officer, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has more than 17 years of experience in biotechnology, including serving in product strategy and director of process development roles at Amgen. His 10 years at Amgen included four years as global operations leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a B.S. in chemical engineering from MIT and is an alumnus of the UCLA Anderson School of Management.